Filtered By:
Condition: Atrial Fibrillation
Countries: Canada Health
This page shows you your search results in order of date. This is page number 6.
Order by Relevance | Date
Total 200 results found since Jan 2013.
Warfarin adherence and anticoagulation control in atrial fibrillation patients: a systematic review
CONCLUSIONS: While the available evidence is limited, this systematic review demonstrated a positive finding of the association between warfarin adherence and anticoagulation control in patients with AF.PMID:34982455 | DOI:10.26355/eurrev_202112_27642
Source: European Review for Medical and Pharmacological Sciences - January 4, 2022 Category: Drugs & Pharmacology Authors: M Ababneh S A Nasser A Rababa'h F Ababneh Source Type: research
FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Abbott Receives European and Canadian Approval for Amplatzer ™ Steerable Delivery Sheath to Optimize Left Atrial Appendage Closure Procedures for People at Risk of Stroke
- First-of-its-kind steerable delivery system designed for left atrial appendage (LAA) occluder to seal the LAA in people who are at increased risk of stroke due to atrial fibrillation
Source: Abbott.com - June 7, 2021 Category: Pharmaceuticals Source Type: news
Improved detection of atrial fibrillation could prevent disabling strokes
(University of Alberta Faculty of Medicine& Dentistry) A clinical trial examining the efficacy of two devices to monitor and detect atrial fibrillation (AF), or an irregular heartbeat, in ischemic stroke patients -- one an implantable device that monitors over 12 months, the other an external device that monitors over a 30-day period -- found the implantable device is more than three times more effective in detecting AF, and both are a significant improvement over the current standard of care in Alberta, Canada.
Source: EurekAlert! - Medicine and Health - June 1, 2021 Category: International Medicine & Public Health Source Type: news
Right anterior mini thoracotomy approach for isolated aortic valve replacement: Early outcomes at a Canadian center
ConclusionThe sternum-sparing RAMT approach can be safely integrated into surgical practice as a minimally invasive alternative for isolated AVR, and can reduce postoperative bleeding and narcotic requirements.
Source: Journal of Cardiac Surgery - May 18, 2021 Category: Cardiovascular & Thoracic Surgery Authors: Ali Fatehi Hassanabad,
Nader Aboelnazar,
Andrew Maitland,
Daniel D Holloway,
Corey Adams,
William D T Kent Tags: ORIGINAL ARTICLE Source Type: research
Dose Specific Effectiveness and Safety of DOACs in Patients with Non-valvular Atrial Fibrillation: a Canadian Retrospective Cohort Study
Direct oral anticoagulants (DOACs) have been proven to be effective and safe for prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). However, suboptimal adherence, variable dosing and use in patient populations that otherwise would have been excluded from clinical trials may impact the efficacy and safety profile of DOACs in a routine care setting. We compared stroke, bleeding, and mortality rates on and off therapy for standard and low-dose DOACs (apixaban, rivaroxaban, dabigatran) versus warfarin in a Canadian cohort.
Source: Thrombosis Research - May 10, 2021 Category: Hematology Authors: Elham Rahme, Richard Godin, Hacene Nedjar, Kaberi Dasgupta, Vicky Tagalakis Source Type: research
EP News: Quality Improvement and Outcomes: Defining and Measuring Atrial Fibrillation Quality Indicators in Canada
In 2016, the Working Group published an initial report identifying and defining priority QIs in 3 distinct categories: access to care, treatment, and outcomes (Can J Cardiol 2016;32:1566, PMID 27297003). An iterative process resulted in the selection of 3 priority QIs: (i) proportion of AF patients at high risk of stroke receiving an oral anticoagulant, (ii) annual rate of stroke, (iii) annual rate of major hemorrhage. A feasibility assessment followed, which determined that none of the QIs as defined could be adequately measured with existing data sources.
Source: Heart Rhythm - April 26, 2021 Category: Cardiology Authors: Roopinder K. Sandhu, Stephen B. Wilton, Anne Marie Smith, Paul Dorian Source Type: research
Trends in Anticoagulant Use at Nursing Home Admission and Variation by Frailty and Chronic Kidney Disease Among Older Adults with Atrial Fibrillation
ConclusionsWhile the proportion of residents with AF receiving oral anticoagulants at admission increased following the approval of DOACs, over 40% remained untreated. Among those treated, use of a DOAC increased, while warfarin use declined. The impact of these recent treatment patterns on the balance between benefit and harm among residents warrant further investigation.
Source: Drugs and Aging - April 21, 2021 Category: Geriatrics Source Type: research
Direct Oral Anticoagulant Choice for Stroke Prevention in Obese Patients with Atrial Fibrillation
Publication date: Available online 15 April 2021Source: Canadian Journal of CardiologyAuthor(s): Tanveer Brar, Doson Chua
Source: Canadian Journal of Cardiology - April 15, 2021 Category: Cardiology Source Type: research
Alcohol consumption and risk of cardiovascular outcomes and bleeding in patients with established atrial fibrillation
CMAJ. 2021 Jan 25;193(4):E117-E123. doi: 10.1503/cmaj.200778.ABSTRACTBACKGROUND: Little is known about the association between alcohol consumption and risk of cardiovascular events in patients with established atrial fibrillation (AF). The main aim of the current study was to investigate the associations of regular alcohol intake with incident stroke or systemic embolism in patients with established AF.METHODS: To assess the association between alcohol consumption and cardiovascular events in patients with established AF, we combined data from 2 comparable prospective cohort studies that followed 3852 patients with AF for ...
Source: Canadian Medical Association Journal - March 5, 2021 Category: General Medicine Authors: Philipp Reddiess Stefanie Aeschbacher Pascal Meyre Michael Coslovsky Michael K ühne Nicolas Rodondi Oliver Baretella J ürg H Beer Richard Kobza Giorgio Moschovitis Marcello Di Valentino Cyrill M üller Fabienne Steiner Leo H Bonati Christian Sticherling Source Type: research
